AHA 2012 Highlights: Multivitamins, Omega-3s, the Polypill, and More

November 19, 2012

Platelet function monitoring and adjustment of treatment based on results after coronary stenting does not improve clinical outcomes . . . and other findings from the AHA Scientific Sessions.

• Multivitamins and omega-3s do not protect against heart disease.

• Coronary bypass is significantly more effective than percutaneous coronary intervention with drug-eluting stents for triple-vessel disease in patients with diabetes.

• The polypill enhances patient adherence to multidrug prevention strategies.

• Platelet function monitoring and adjustment of treatment based on results after coronary stenting does not improve clinical outcomes.

These findings made news among the late-breaking clinical trials presented at the American Heart Association’s 2012 Scientific Sessions in Los Angeles last week. These and other study results are also making headlines in the popular media and you may get questions from patients. Here, AHA Chair for the Committee on Scientific Sessions Dr Elliott Antman talks to CardiologyNow host Dr Payal Kohli about study results that may have direct impact on day-to-day primary care practice.

 

Podcast: AHA 2012 Highlights


Additional study details are available here:

FREEDOM Trial-Strategies for multivessel revascularization in patients with diabetes.
--AHA Summary Slide

ARCTIC -A randomized trial of bedside platelet function monitoring to adjust antiplatelet therapy vs Standard of care in patients undergoing drug eluting stent implantation.
--AHA Summary Slide

OPERA-Omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: results of a double-blind randomized clinical trial
--AHA Summary Slide

The Physician’s Health Study II-A randomized trial of a multivitamin (MVM) in the prevention of cardiovascular disease in men.
--AHA Summary Slide

UMPIRE-Use of a multidrug pill in reducing cardiovascular events.
--AHA Summary Slide

CardiologyNow host Dr Payal Kohli is a cardiology fellow at the University of California San Francisco, and Dr Antman is Professor of Medicine, Brigham and Women's Hospital, Senior Investigator, TIMI Study Group, and Associate Dean for Clinical/Translational Research at Harvard Medical School, all in Boston, Massachusetts.